



**meetings
in a box**

ROAD TO



ESGO 2025

A cura di Alessia Levaggi, Genova

ENDOMETRIAL CANCER

ENGOT-En11/GOG-3053/KEYNOTE-B21 Study Pembrolizumab or placebo plus adj CT with or without RT in newly diagnosed, high-risk EC (Abs 637)

DUO-E/GOG-3041/ENGOT-EN10 Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as 1 line for EC (Abs 939-978)

ENGOT-EN5/GOG-3055/SIENDO Selinexor maintenance therapy for patients with TP53 wt advanced or recurrent EC (Abs 372)

OVARIAN CANCER

ENGOT-OV43/GOG-3036/KEYLYNK-001 CT with or without pembrolizumab followed by maintenance with olaparib or placebo for 1 line of advanced BRCA non-mutated EOC (Abs 128)

GGER-01 3 vs 6 courses of neoadj carboplatin-paclitaxel CT in stage IIIC or IV OC (Abs 442)

CERVICAL CANCER

ENGOTCx11/GOG-3047/KEYNOTE-A18 Study Pembrolizumab plus CT/RT for high-risk LACC (Abs 691)

ATEZOLACC Trial Atezolizumab in combination with CT/RT in LACC (Abs 152)

MITO CERV3 Study Carboplatin-paclitaxel pembrolizumab in neoadj treatment of LACC (Abs 1258)